argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline

argenx announced an acquisition of Forte Biosciences, securing the anti-CD122 antibody FB102—a novel immunology candidate currently in Phase 1b trials. This transaction builds upon argenx's existing strategic investment, signaling disciplined M&A discipline focused on proprietary biology rather than exploratory venture.

The strategic rationale centers on CD122 biology, a differentiated mechanism targeting pathogenic T-cell and NK-cell activity. Early Phase 1b validation in vitiligo and celiac disease demonstrates proof-of-concept in high-unmet-need indications lacking recent innovation. This "pipeline-in-a-product" approach reduces clinical development risk by incorporating validated biology into argenx's established immunology infrastructure.

For FBRX shareholders, the acquisition provides liquidity and de-risks clinical advancement under a well-capitalized partner. For ARGX, the deal expands competitive moat in autoimmune and dermatological segments while diversifying its mechanism-of-action portfolio beyond existing programs.

Sector implication: This transaction reflects continued investor appetite for immunology innovation, particularly in novel T-cell targeting mechanisms. The deal reinforces Health Care consolidation trends where larger biotechs acquire specialized platforms to accelerate pipeline density and mitigate early-stage clinical risk. Unmet-need positioning in vitiligo and celiac disease suggests strong commercial tailwinds if efficacy validates.